Green propolis as an adjuvant against nontuberculous mycobacteria

• Autor(a) principal: Allend,Suzane Olachea
• Data de Publicação: 2021
• Outros Autores: Volcão,Lisiane, Canielles,Carolina da Silva, Barbosa,Israel, Biatobock,Dara, Silva,Pedro Eduardo Almeida da, Ramos,Daniela Fernandes
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Rodriguésia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2175-78602021000100295
• topic: additivity; antimicrobial; Mycobacterium sp.; propolis

Abstract Natural products have been touted as important tools because of their vast potential for the development of compounds with antimicrobial activity and the possible inhibitory activity and/or adjuvant resistance mechanisms. Propolis has been empirically used for many years for the treatment of diseases, mainly due to its antioxidant, anti inflammatory and antimicrobial activities. This study aimed to evaluate the in vitro antimycobacterial activity of the ethanol extract of propolis alone and in combination with rifampicin (RIF), amikacin (AMI) and ciprofloxacin (CIP). The ethanol extract of propolis showed antibacterial activity against Mycobacterium chelonae and M. kansasii and was capable of increasing AMI, RIF and CIP activity in combination. On the other hand, compared to M. absecessus, M. fortuitum and M. avium, the extract was not active at 200 µg/mL and did not show pronounced adjuvant capacity when evaluated in association with the drugs. Based on these results, it can be concluded that the ethanol extract of propolis could be an alternative in the development of new drugs and can be used complementary with the current mycobacteriosis treatment.